ReviewF1000Research2017
The evolution of medulloblastoma therapy to personalized medicine.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- SEOM clinical guideline for management of adult medulloblastoma (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Guideline
- Article
- High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.Neuro-oncology · 2025Article
- Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level.Nature communications · 2024Article
- Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.Acta neurochirurgica · 2024Article
- IGFBP2 promotes proliferation and cell migration through STAT3 signaling in Sonic hedgehog medulloblastoma.Acta neuropathologica communications · 2023Article
- Review
- The Alliance AMBUSH Trial: Rationale and Design.Cancers · 2022Review
- Review
- Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.PloS one · 2021Article
- Precision Medicine, AI, and the Future of Personalized Health Care.Clinical and translational science · 2021Review
- Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.Frontiers in oncology · 2021Review
- Real-world data for pediatric medulloblastoma: can we improve outcomes?European journal of pediatrics · 2021Article
- Medulloblastoma: "Onset of the molecular era".Molecular biology reports · 2020Review
- Drug Repurposing in Medulloblastoma: Challenges and Recommendations.Current treatment options in oncology · 2020Review
- Thioredoxin System Protein Expression Is Associated with Poor Clinical Outcome in Adult and Paediatric Gliomas and Medulloblastomas.Molecular neurobiology · 2020Article
- Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma.Cancers · 2020Review
- Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma.Scientific reports · 2019Article
- Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes.Bioinformatics (Oxford, England) · 2019Article
- Examining the biomarkers and molecular mechanisms of medulloblastoma based on bioinformatics analysis.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Recent advances in cancer genomics have revolutionized the characterization and classification of medulloblastomas. According to the current WHO guidelines, medulloblastomas are now classified into the following molecularly defined groups: Wnt signaling pathway (WNT)-activated, sonic hedgehog signaling pathway (SHH)-activated and tumor suppressor protein p53 (TP53)-mutant, SHH-activated and TP53-wildtype, and non-WNT/non-SHH (i.e. group 3 and group 4). Importantly, genomic, epigenomic, and proteomic advances have created a potential paradigm shift in therapeutic options. The challenge now is to (i) translate these observations into new therapeutic approaches and (ii) employ these observations in clinical practice, utilizing the classification following a molecular analysis for diagnosis and application of new subgroup-specific targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.